TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 679080

Group type: EXPERIMENTAL
Intervention: Systemic cephaloridine perioperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral neomycin and erythromycin base preoperatively
Number of subjects: 0
Study: 31842026

Group type: EXPERIMENTAL
Intervention: Doxapram 1 mg/kg ideal body weight
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no doxapram)
Number of subjects: 100
Study: 30019629

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Stroke mimics
Number of subjects: 1091
Study: 28829992

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 267

Group type: COMPARATOR
Intervention: Fluorouracil-cisplatin
Number of subjects: 267
Study: 26414847

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Laparoscopic Donor Nephrectomy (RDN)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard Laparoscopic Donor Nephrectomy (LDN)
Number of subjects: 45
Study: 23644928

Group type: EXPERIMENTAL
Intervention: Sodium selenite at 750 microg/24 h for 6 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 21710401

Group type: EXPERIMENTAL
Intervention: Second-Generation Antipsychotics (SGAs)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Clinical and trial-related barriers
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Drug company representatives as information source
Number of subjects: 278
Study: 19704100

Group type: EXPERIMENTAL
Intervention: ICD treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16001181

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day plus calcium 1,000 mg/day and vitamin D 800 IU/day
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control (alfacalcidol 1 mug/day plus calcium 500 mg/day or vitamin D 1,000 IU/day plus calcium 800 mg/day)
Number of subjects: 316
Study: 15167985

Group type: EXPERIMENTAL
Intervention: Vibrating platform device (10 min/day for 6 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment (10 min/day for 6 months)
Number of subjects: 24
Study: 11746532

Group type: EXPERIMENTAL
Intervention: Filtration leukocytapheresis (LCP), repeated three times at 1-week intervals.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Filtration leukocytapheresis (LCP) in responder subgroup.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Filtration leukocytapheresis (LCP) in both subgroups.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (sham apheresis), n=7.
Number of subjects: 22
Study: 9423948

Group type: EXPERIMENTAL
Intervention: Group I (n = 26) using the new retrograde cardioplegia cannula with a long balloon (3 cm)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Group II (n = 26) using a standard cannula (balloon length 8 mm)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group I (n = 26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Group II (n = 26)
Number of subjects: 52
Study: 7534945

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dextran 70 and Enoxaparin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of Enoxaparin and Dextran
Number of subjects: 12
Study: 3297566

Group type: EXPERIMENTAL
Intervention: Manual dilatation of the anus
Number of subjects: 111

Group type: COMPARATOR
Intervention: Lateral subcutaneous sphincterotomy
Number of subjects: 111
Study: 30169321

Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 26839889

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDI4 (four injections daily, glargine based)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDI3 (three injections daily, aspart 30-based)
Number of subjects: 0
Study: 24730050

Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5mg q4h)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 506
Study: 22687231

Group type: EXPERIMENTAL
Intervention: Higher numbers of drugs prescribed during follow-up
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Decreased energy intake
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 597

Group type: COMPARATOR
Intervention: Baseline characteristics (older individuals, males, larger waist circumference)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Modelled CVD risk after 14 months
Number of subjects: 597
Study: 20687970

Group type: EXPERIMENTAL
Intervention: Multifibre mixture with prebiotic components
Number of subjects: 27

Group type: COMPARATOR
Intervention: Fibre-free period
Number of subjects: 27
Study: 19248655

Group type: EXPERIMENTAL
Intervention: MA 60 mg/kg/day/ IM and oral placebo for three weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MA 30 mg/kg/day/IM and oral omeprazole 40 mg/day for three weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: MA 30 mg/kg/day/IM and oral placebo for three weeks
Number of subjects: 150
Study: 15993827

Group type: EXPERIMENTAL
Intervention: Gap selection based on vehicle distance
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Gap selection based on time-of-arrival
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Gap selection by old-old adults
Number of subjects: 3
Study: 12970225

Group type: EXPERIMENTAL
Intervention: RV to PA conduit (RV/PA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt (BTS)
Number of subjects: 56
Study: 10629357

Group type: EXPERIMENTAL
Intervention: eptastigmine 10 mg t.i.d. and 12 mg t.i.d. for 25 weeks
Number of subjects: 349

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: eptastigmine
Number of subjects: 349
Study: 8795261

Group type: EXPERIMENTAL
Intervention: 18 instructional visits
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 instructional visits
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 instructional visits
Number of subjects: 0
Study: 1621223

Group type: EXPERIMENTAL
Intervention: IVIG + A
Number of subjects: 80

Group type: COMPARATOR
Intervention: A
Number of subjects: 80
Study: 6827407

Group type: EXPERIMENTAL
Intervention: Treatment group (53 children)
Number of subjects: 181

Group type: COMPARATOR
Intervention: No-treatment group (128 children)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Both treated and untreated children
Number of subjects: 181

Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Children with increased sensitivity
Number of subjects: 181
Study: 31123008

Group type: EXPERIMENTAL
Intervention: Amoxicillin 70-90 mg/kg/day for 3 or 7 days
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Amoxicillin 35-50 mg/kg/day for 3 or 7 days
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Amoxicillin (both dosages)
Number of subjects: 800
Study: 30192166

Group type: EXPERIMENTAL
Intervention: meropenem/colistin
Number of subjects: 47

Group type: COMPARATOR
Intervention: meropenem/ampicillin-sulbactam
Number of subjects: 47
Study: 27427128

Group type: EXPERIMENTAL
Intervention: Protocol-based procedure (Group A)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Random shunt placement (Group B)
Number of subjects: 210
Study: 25175805

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5042

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5042
Study: 22002249

Group type: EXPERIMENTAL
Intervention: Moderate treatment (simple, low-cost environmental modifications)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intense treatment (added elements to engage management)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both treatment conditions (moderate vs. intense)
Number of subjects: 0
Study: 19459810

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 20
Study: 17325603

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Nonnucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Protease inhibitor + Nonnucleoside reverse transcriptase inhibitor (PI + NNRTI)
Number of subjects: 422
Study: 15167542

Group type: EXPERIMENTAL
Intervention: Virtual reality
Number of subjects: 0

Group type: COMPARATOR
Intervention: No virtual reality
Number of subjects: 0
Study: 11449531

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 micrograms/daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 840 micrograms/daily
Number of subjects: 16
Study: 9684692

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) administered before meals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) administered during meals
Number of subjects: 12
Study: 7511495

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (6% wt/vol, average molecular weight 200 kilodaltons)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Human albumin (5% albumin solution)
Number of subjects: 10
Study: 2894751

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) infusion (20 mU/kg/h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study: 29386053

Group type: EXPERIMENTAL
Intervention: Routine removal of the syndesmotic screw
Number of subjects: 194

Group type: COMPARATOR
Intervention: Removal on demand of the syndesmotic screw
Number of subjects: 194
Study: 27058712

Group type: EXPERIMENTAL
Intervention: Deep sedation with midazolam
Number of subjects: 80

Group type: COMPARATOR
Intervention: Moderate sedation with midazolam
Number of subjects: 80
Study: 23889803

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (cataract surgery patients)
Number of subjects: 24
Study: 22356350

Group type: EXPERIMENTAL
Intervention: MP29-02
Number of subjects: 6

Group type: COMPARATOR
Intervention: MP29-02-FP-mono
Number of subjects: 6

Group type: COMPARATOR
Intervention: FP-BI
Number of subjects: 6
Study: 20052461

Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib (n = 8)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 12
Study: 18323726

Group type: EXPERIMENTAL
Intervention: Meridian massage (20 min, 3 times per week for 4 weeks)
Number of subjects: 34
Study: 17117227

Group type: EXPERIMENTAL
Intervention: Intrapericardial triamcinolone hexacetonide 200 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Oral prednisone plus intrapericardial placebo
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intrapericardial 0.9% saline (placebo)
Number of subjects: 57
Study: 14664167

Group type: EXPERIMENTAL
Intervention: Arifon retard monotherapy
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination of arifon retard and climonorm
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Arifon retard in combination with climonorm
Number of subjects: 95
Study: 10655249

Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes in women
Number of subjects: 5653

Group type: EXPERIMENTAL
Intervention: Fasting insulin levels in women
Number of subjects: 5653

Group type: EXPERIMENTAL
Intervention: C-peptide levels in women
Number of subjects: 5653

Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes in men
Number of subjects: 5653

Group type: EXPERIMENTAL
Intervention: Fasting insulin and C-peptide in men
Number of subjects: 5653
Study: 8987189

Group type: EXPERIMENTAL
Intervention: Nortriptyline-fluphenazine (NF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carbamazepine (CMZ)
Number of subjects: 16
Study: 1338389

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg once daily for 24 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo once daily for 24 weeks
Number of subjects: 48
Study: 6711261

Group type: EXPERIMENTAL
Intervention: suxamethonium 0.1 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: sodium chloride
Number of subjects: 40
Study: 30257036

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) and deproteinized bovine bone mineral (DBBM)
Number of subjects: 9
Study: 30235759

Group type: EXPERIMENTAL
Intervention: Secondary hospitals
Number of subjects: 896

Group type: COMPARATOR
Intervention: Tertiary hospitals
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 896
Study: 27322462

Group type: EXPERIMENTAL
Intervention: 5mg finasteride daily for 4-6 weeks
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 24224738

Group type: EXPERIMENTAL
Intervention: 10-week aerobic training programme, 3 sessions per week, treadmill exercise (30-40 min) at 55-65% of peak heart rate
Number of subjects: 20

Group type: COMPARATOR
Intervention: No training programme
Number of subjects: 20
Study: 22488225

Group type: EXPERIMENTAL
Intervention: Passive hamstring stretching (3 times for 30 seconds)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No stretching or movement (Control)
Number of subjects: 34
Study: 20416389

Group type: EXPERIMENTAL
Intervention: Inhaled magnesium sulfate (333 mg in 3 ml solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (3 ml isotonic saline solution with albuterol and ipratropium)
Number of subjects: 60
Study: 17700289

Group type: EXPERIMENTAL
Intervention: GDx‐VCC
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: GDx‐VCC combined with M‐FDT
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: NFI combined with GDx‐VCC nerve fiber bundle defect criterion
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Triple combination of M‐FDT with the latter pair of criteria
Number of subjects: 181
Study: 16432644

Group type: EXPERIMENTAL
Intervention: Mailed educational intervention (three mailings)
Number of subjects: 1185
Study: 14571485

Group type: EXPERIMENTAL
Intervention: Stent intervention
Number of subjects: 955
Study: 10730980

Group type: COMPARATOR
Intervention: PGF2alpha treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Progesterone treatment (100 mg daily from Days 10 to 30)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 8803525

Group type: EXPERIMENTAL
Intervention: S-1452 (50 mg) with food
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: S-1452 (50 mg) without food
Number of subjects: 8

Group type: COMPARATOR
Intervention: S-1452 (50 mg) with food and without food
Number of subjects: 8
Study: 1630666

Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 0
Study: 6142348

Group type: EXPERIMENTAL
Intervention: Ingestion of one extra-large egg for three weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ingestion of isocaloric eggless foods for three weeks
Number of subjects: 17
Study: 31863465

Group type: EXPERIMENTAL
Intervention: Real-world data collection from electronic health records, mobile applications, wearables, and social media
Number of subjects: 0
Study: 30936313

Group type: EXPERIMENTAL
Intervention: Brief science-based online diversity training
Number of subjects: 3016

Group type: COMPARATOR
Intervention: Active placebo control
Number of subjects: 3016
Study: 28489511

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg twice per day)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 25380077

Group type: COMPARATOR
Intervention: Shared care
Number of subjects: 287

Group type: COMPARATOR
Intervention: Nurse consultations
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Rheumatologist consultations
Number of subjects: 287
Study: 23187951

Group type: EXPERIMENTAL
Intervention: 3 g of β‐glucans daily for 8 weeks
Number of subjects: 59
Study: 21489769

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.625 mg/mL with epinephrine 5 μg/mL at 10 mL/hr
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.625 mg/mL at 10 mL/hr
Number of subjects: 60
Study: 19069713

Group type: EXPERIMENTAL
Intervention: Perineural injection of 1 ml of betamethasone after surgical decompression
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical decompression of the median nerve by open release of the carpal tunnel
Number of subjects: 40
Study: 17023253

Group type: EXPERIMENTAL
Intervention: Concentric needle electrode
Number of subjects: 80

Group type: COMPARATOR
Intervention: Monopolar needle electrode
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Concentric needle electrode (APB muscle)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Biceps muscle (Monopolar needle)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Needle preference (Concentric)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Needle preference (Monopolar)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Needle preference
Number of subjects: 80
Study: 15332470

Group type: EXPERIMENTAL
Intervention: Hospice at home (HAH)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Perceptions of inadequate terminal support
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High symptom severity
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Home deaths
Number of subjects: 96

Group type: COMPARATOR
Intervention: Inpatient deaths
Number of subjects: 96
Study: 11078298

Group type: EXPERIMENTAL
Intervention: Cardiologist A's interpretation of angiographic reports
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cardiologist B's interpretation of angiographic reports
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Unanimous agreement on the number of narrowed arteries
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Actual management vs. Cardiologist A's recommendations
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Actual management vs. Cardiologist B's recommendations
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cardiologist B's agreement in the subset of 92 patients
Number of subjects: 209
Study: 9403286

Group type: EXPERIMENTAL
Intervention: Light breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cooked breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 0
Study: 1402291

Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 27

Group type: COMPARATOR
Intervention: 0.5% timolol (Control)
Number of subjects: 27
Study: 3913752

Group type: EXPERIMENTAL
Intervention: L-5-Hydroxytryptophan (L-5-HTP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29533686

Group type: EXPERIMENTAL
Intervention: MIES-1 (single serving)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MIES-2 (two servings)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MIES (all doses)
Number of subjects: 24
Study: 30427213

Group type: EXPERIMENTAL
Intervention: PIPATIC program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard cognitive‐behavioral therapy (CBT)
Number of subjects: 31
Study: 26970721

Group type: EXPERIMENTAL
Intervention: LAM-guided anti-tuberculosis treatment initiation
Number of subjects: 2528

Group type: COMPARATOR
Intervention: Routine diagnostic tests alone (no LAM)
Number of subjects: 2528
Study: 24524676

Group type: EXPERIMENTAL
Intervention: CNS stimulants (methylphenidate or dexamphetamine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21681140

Group type: EXPERIMENTAL
Intervention: Discectomy (surgery)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Nonoperative care (control)
Number of subjects: 1192
Study: 20033810

Group type: EXPERIMENTAL
Intervention: CCRT with docetaxel, cisplatin, and 5-fluorouracil (TPF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CCRT with cisplatin, 5-fluorouracil, methotrexate, and leucovorin (PFML)
Number of subjects: 100
Study: 17426304

Group type: EXPERIMENTAL
Intervention: Diabetes Problem-Solving Scale (DPSS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: DPSS subscales (Impulsive Style, Negative Transfer of Past Experience/Learning, Negative Motivation)
Number of subjects: 64
Study: 16385425

Group type: EXPERIMENTAL
Intervention: Abbreviated Progressive Relaxation Training (APRT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (quiet sitting)
Number of subjects: 55
Study: 11871363

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 535

Group type: COMPARATOR
Intervention: Ipratropium 40 microg q.i.d.
Number of subjects: 535
Study: 9854457

Group type: EXPERIMENTAL
Intervention: Methacholine (2 and 4 micrograms/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (5 and 10 micrograms/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Local intra-arterial noradrenaline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline infusions
Number of subjects: 27
Study: 7608855

Group type: EXPERIMENTAL
Intervention: Repeated expression of attitudes during group discussions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group members instructed to use each other's arguments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group members instructed to avoid using each other's arguments
Number of subjects: 0
Study: 2096040

Group type: EXPERIMENTAL
Intervention: Cefalozin
Number of subjects: 3137

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 3137

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 3137
Study: 361281

Group type: EXPERIMENTAL
Intervention: Flunisolide 300 microgram/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 30831454

Group type: EXPERIMENTAL
Intervention: Paliperidone-extended release formulation
Number of subjects: 602
Study: 27609242

Group type: EXPERIMENTAL
Intervention: Citalopram treatment (open group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment (placebo-controlled group)
Number of subjects: 0
Study: 26090572

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 600

Group type: COMPARATOR
Intervention: qHPV vaccine
Number of subjects: 600